Granted Patent
B2
US 12,410,246 · App. 18/500,622 · Granted Sep 9, 2025
Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
Assignee:
Opsidio, LLC
C07K16/24A61P11/00A61P11/06A61P29/00A61P37/08C12N15/63A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/76C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders.
Claims (3)
1. An isolated nucleic acid encoding an antibody, comprising a heavy chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 1, 2, and 3, respectively; and a light chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 4, 5, and 6, respectively.
2. An expression vector comprising a nucleic acid encoding an antibody, comprising a heavy chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 1, 2, and 3, respectively; and a light chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 4, 5, and 6, respectively.
3. An isolated host cell comprising the expression vector of claim 2 .
Assignments (5)
PATENT SECURITY AGREEMENT (2L)
Recorded Apr 6, 2026
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS PURCHASER
Reel/Frame 075416/0660 →
PATENT SECURITY AGREEMENT (1L)
Recorded Apr 6, 2026
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075416/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2026
From: PHILLIPS, MARTIN
To: OPSIDIO, LLC
Reel/Frame 073739/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 13, 2026
From: OPSIDIO, LLC
To: INSMED INCORPORATED
Reel/Frame 073451/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 6, 2023
From: PHILLIPS, MARTIN
To: OPSIDIO, LLC
Reel/Frame 065468/0123 →
Continuity (3)
Provisional Application
62900927
· Sep 16, 2019
References Cited (104)
US 4816397A
· Boss et al.
· 1989
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5911988A
· Brownell et al.
· 1999
[cited by applicant]
US 6331415B1
· Cabilly et al.
· 2001
[cited by applicant]
US 7285640B2
· Takeuchi et al.
· 2007
[cited by applicant]
US 8911729B2
· Lukacs
· 2014
[cited by examiner]
US 9353178B2
· Lukacs et al.
· 2016
[cited by applicant]
US 20040214272A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20080248050A1
· Stevens
· 2008
[cited by applicant]
US 20080305074A1
· Zsebo et al.
· 2008
[cited by applicant]
US 20110189093A1
· Moffett et al.
· 2011
[cited by applicant]
US 20150018408A1
· Lukacs et al.
· 2015
[cited by applicant]
US 20170152315A1
· Hansen et al.
· 2017
[cited by applicant]
US 20200255509A1
· Lukacs et al.
· 2020
[cited by applicant]
US 20220324957A1
· Phillips
· 2022
[cited by applicant]
US 20220340655A1
· Phillips
· 2022
[cited by applicant]
US 20230019680A1
· Phillips
· 2023
[cited by applicant]
US 20240182556A1
· Bradbury
· 2024
[cited by applicant]
CN 1889979A
· 2007
[cited by applicant]
JP 3583214B2
· 2004
[cited by applicant]
KR 20170022409A
· 2017
[cited by applicant]
KR 20190049483A
· 2019
[cited by applicant]
RU 2681730C2
· 2019
[cited by applicant]
WO WO9109967A1
· 1991
[cited by applicant]
WO WO9202551A1
· 1992
[cited by applicant]
WO WO2005058815A2
· 2005
[cited by applicant]
WO WO2006002064A2
· 2006
[cited by applicant]
WO WO2012096960A2
· 2012
[cited by applicant]
WO WO2014018625A1
· 2014
[cited by applicant]
WO WO2017029583A2
· 2017
[cited by applicant]
WO WO2017035430A2
· 2017
[cited by examiner]
WO WO2017112829A1
· 2017
[cited by applicant]
WO WO2018067071A1
· 2018
[cited by applicant]
WO WO2019066093A1
· 2019
[cited by applicant]
WO WO2019088658A1
· 2019
[cited by applicant]
WO WO2020081920A1
· 2020
[cited by applicant]
WO WO2021055408A1
· 2021
[cited by applicant]
WO WO2021055409A1
· 2021
[cited by applicant]
WO WO2022197914A2
· 2022
[cited by applicant]
Mateu MG, et. al. Eur J Immunol. Jun. 1992;22(6):1385-9 (Year: 1992).
[cited by examiner]
Brown et al., J Immunol. May 1996;156(9):3285-91 (Year: 1996).
[cited by examiner]
Greenspan et al. 1999 Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999).
[cited by examiner]
Keller et al, The Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense (2001):877-897 (Year: 2001).
[cited by examiner]
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416 (Year: 2002).
[cited by examiner]
Trier et al, Methods 56 (2012) 136-144 (Year: 2012).
[cited by examiner]
Li et al, Vaccines 2014, 2, 515-536 (Year: 2014).
[cited by examiner]
Fonseca et al, Mucosal Immunol. Mar. 2019 ; 12(2): 445-456 (Year: 2019).
[cited by examiner]
Lebron, N. B., et al., “A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth”, Cancer Biology & Therapy (Sep. 2014); 15(9): 1208-1218.
[cited by applicant]
Abts, H., et al., “CD20 positive human B lymphocytes separated with the magnetic cell sorter (MACS) can be induced to proliferation and antibody secretion in vitro”, Journal of Immunological Methods (1989); 125(1-2): 19…
[cited by applicant]
Alam, M. E., et al., “Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with high colloidal stability”, Molecular Pharmaceutics (2018); 15(1): 150-163.
[cited by applicant]
Berlin, Aaron A., et al., “Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma”, Laboratory Investigation (Jun. 2006); 86(6): 557-565.
[cited by applicant]
Boder, E. T., et al., “Yeast surface display for screening combinatorial polypeptide libraries”, Nature Biotechnology (1997); 15(6): 553-557.
[cited by applicant]
Co-pending U.S. Appl. No. 18/550,438, inventor Bradbury; Andrew RM, filed Sep. 13, 2023.
[cited by applicant]
Crooks, G. E., et al., “WebLogo: a sequence logo generator”, Genome Research (2004); 14(6): 1188-1190.
[cited by applicant]
Da Silva, C., et al., “Stem cell factor expression, mast cells and inflammation in asthma”, Fundamental & Clinical Pharmacology (2006); 20(1): 21-39.
[cited by applicant]
Ding, Lin, et al., “Essential role of stem cell factor—c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis”, The Journal of Pathology (Jun. 2013); 230(2): 205-214.
[cited by applicant]
El Kossi, Mohsen MH, et al., “Stem cell factor and crescentic glomerulonephritis”, American Journal of Kidney Diseases (Apr. 2003); 41(4): 785-795.
[cited by applicant]
El-Koraie, Ahmed F., et al., “Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides”, Kidney International (2001); 60(1): 167-172.
[cited by applicant]
Extended European Search Report for Application No. EP20865210.7, mailed on Oct. 27, 2023, 8 pages.
[cited by applicant]
Extended European Search Report for European Application No. EP20866530.7 dated Sep. 18, 2023, 7 pages.
[cited by applicant]
Ferrara, F., et al., “Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker”, PloS one (2012); 7(11): e49535; 12 pages.
[cited by applicant]
Fonseca, Wendy, et al., “Group 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease”, Mucosal Immunology (2019); 12(2): 445-456.
[cited by applicant]
Garcia-Hernandez, V., et al., “Inhibition of Soluble Stem Cell Factor Promotes Intestinal Mucosal Repair”, Inflammatory Bowel Diseases (2023); 29(izad003): 1133-1144.
[cited by applicant]
GenBank Accession No. AML31316.1, “immunoglobulin heavy chain variable region, partial [
[cited by applicant]
GenBank Accession No. OGS00894.1, “hypothetical protein A3G85_00225 [Elusimicrobia bacterium RIFCSPLOWO2_12_FULL_39_28]”, Jul. 8, 2016 [retrieved Jan. 25, 2021] [online] Retrieved from the Internet, https://www.ncbi.nlm…
[cited by applicant]
Hunter, S. A., et al., “Cell-binding assays for determining the affinity of protein-protein interactions: technologies and considerations”, Methods in Enzymology (2016); 580: 21-44.
[cited by applicant]
International Application No. PCT/US2020/050973, International Preliminary Report on Patentability mailed Mar. 15, 2022, 6 pages.
[cited by applicant]
International Application No. PCT/US2020/050973, International Search Report and Written Opinion mailed Feb. 19, 2021, 11 pages.
[cited by applicant]
International Application No. PCT/US2020/050973, Invitation to Pay Additional Fees mailed Dec. 14, 2020, 2 pages.
[cited by applicant]
International Application No. PCT/US2020/050974, International Preliminary Report on Patentability dated Mar. 15, 2022, 6 pages.
[cited by applicant]
International Application No. PCT/US2020/050974, International Search Report and Written Opinion dated Feb. 24, 2021, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/020732 dated Sep. 28, 2023, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/020732, mailed on Sep. 2, 2022, 22 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US22/20732, dated Jul. 5, 2022, 3 pages.
[cited by applicant]
Kelly, R. L., et al., “Reduction of nonspecificity motifs in synthetic antibody libraries”, Journal of Molecular Biology (2018); 430(1): 119-130.
[cited by applicant]
Li, X., et al., “Glutamine deamidation: differentiation of glutamic acid and γ-glutamic acid in peptides by electron capture dissociation”, Analytical Chemistry (2010); 82(9): 3606-3615.
[cited by applicant]
Lowenthal, M. S., et al., “Identification of novel N-glycosylation sites at noncanonical protein consensus motifs”, Journal of Proteome Research (2016); 15(7): 2087-2101.
[cited by applicant]
Lukacs, N. W., “Therapeutic Mabs for Chronic Kidney Disesase”, National Institute of Health (2019) [online] https://grantome.com/grant/NIH/R41-DK112426-01 (Access Date: Oct. 1, 20237); 3 pages.
[cited by applicant]
Mendiaz, Elizabeth A., et al., “Epitope mapping and immunoneutralization of recombinant human stem-cell factor”, European Journal of Biochemistry (1996); 239(3): 842-849.
[cited by applicant]
Orr-Urtreger, Avi, et al., “Developmental expression of c-kit, a proto-oncogene encoded by the W locus”, Development (1990); 109(4): 911-923.
[cited by applicant]
Orr-Weaver, T. L., et al., “Yeast transformation: a model system for the study of recombination”, Proceedings of the National Academy of Sciences (1981); 78(10): 6354-6358.
[cited by applicant]
Powell, D. W., et al., “Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer”, American Journal of Physiology-Gastrointestinal and Liver Physiology (2005); 289(1):…
[cited by applicant]
Powell, D. W., et al., “Myofibroblasts. II. Intestinal subepithelial myofibroblasts”, American Journal of Physiology—Cell Physiology (1999); 277(2): C183-C201.
[cited by applicant]
Rasky, Andrew, et al., “Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease”, American Journal of Physiology—Lung Cellular and Molecular Physiology (2020); 318(1): L…
[cited by applicant]
Sydow, J. F., et al., “Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions”, PloS one (2014); 9(6): e100736; 13 pages.
[cited by applicant]
Tiller, K. E., et al., “Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs”, Journal of Biological Chemistry (2017); 292(40): 16638-16652.
[cited by applicant]
UniProtKB Accession A0A1G7FT53, “Uncharacterized protein”, May 8, 2019, [online] Retrieved from the Internet, https://www.uniprot.org/uniprot/A0A1G7FT53.txt?version=4 , 1 page.
[cited by applicant]
Vlasak, J., et al., “Fragmentation of monoclonal antibodies”, Mabs (2011); 3(3): 253-263.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/053041 mailed Feb. 18, 2025, 14 pages.
[cited by applicant]
Tayel et al.., “Association of stem cell factor gene expression with severity and atopic state in patients with bronchial asthma.”, Respir Res. Jan. 18, 2017; 18(1): 21, 8 pages.
[cited by applicant]
Holliger, P., et al., “Engineered antibody fragments and the rise of single domains”, Nature Biotechnology (2005); 23(9): 1126-1136.
[cited by applicant]
Invitation to Pay Additional fees for International Application No. PCT/US2024/053041, mailed Dec. 6, 2024, 2 pages.
[cited by applicant]
Kohler, G., et al., “Pillars Article: Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, The Journal of Immunology (Mar. 2005); 174(5): 2453-2455. Reprinted with permission from Nature (Ma…
[cited by applicant]
Mountain, A., et al., “Engineering antibodies for therapy”, Biotechnology & Genetic Engineering Reviews (1992); 10(1): 1-142.
[cited by applicant]
Riechmann, L., et al.; “Reshaping human antibodies for therapy,” Nature; 332(6162):323-327 (1988).
[cited by applicant]
Simmons, L. C., et al., “Expression of full-length immunoglobulins in
[cited by applicant]
Verma, R., et al., “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems”, Journal of Immunological Methods (Jul. 1998); 216(1-2): 165-181.
[cited by applicant]